eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review

Joanna Narbutt
1
,
Rafał Czajkowski
2
,
Aleksandra Lesiak
1
,
Witold Owczarek
3
,
Adam Reich
4
,
Jacek C. Szepietowski
5

1.
Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
2.
Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
3.
Department of Dermatology, Military Institute of Medicine, Warsaw, Poland
4.
Department of Dermatology, University of Rzeszow, Rzeszow, Poland
5.
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland
Adv Dermatol Allergol 2021; XXXVIII (5): 727-733
Online publish date: 2021/11/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Psoriasis vulgaris is a chronic, immune-mediated disorder, which has a substantial impact on all aspects of patients’ quality of life. In most patients, the disease is mild to moderate and is successfully treated with topical agents. The most common therapy involves a vitamin D3 analogue (calcipotriene) in combination with a synthetic corticosteroid (betamethasone dipropionate). The aerosol vehicle (foam) with softening properties is another formulation of this combination drug, apart from ointment and gel, expanding the therapeutic options available to patients with psoriasis. The article describes the pharmacokinetic and pharmacodynamic properties of calcipotriene/betamethasone dipropionate foam. The results of the key randomised clinical studies investigating the efficacy, including patients’ quality of life and safety of the foam versus ointment, gel and either active ingredient in foam vehicle are presented. In addition, the results of a study on maintenance treatment with calcipotriene/betamethasone dipropionate foam as well as reports on real-world use of this medicine in patients with psoriasis, are discussed.
keywords:

psoriasis vulgaris, calcipotriene, betamethasone dipropionate, foam, topical administration

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.